Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Ipamorelin and CJC-1295 — mechanism, dosing, side effects, legal status, and pricing.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) originally developed by Novo Nordisk and later advanced by Helsinn/Nycomed. It is a selective ghrelin receptor agonist / growth hormone secretagogue (GHRP). Its defining feature versus older GHRPs (GHRP-2, GHRP-6, hexarelin) is that in preclinical and early clinical studies it raised GH without meaningfully increasing ACTH, cortisol, or prolactin. It is not FDA-approved for any indication; a Phase 2 trial for postoperative ileus failed to meet its primary endpoint and clinical development was discontinued. In the wellness/grey market it is sold as a research chemical and used off-label for anti-aging and body-composition goals despite no clinically validated human dose for those uses.
CJC-1295 is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH 1-29) originally developed by ConjuChem. The name historically refers to the DAC-modified (Drug Affinity Complex) form that covalently binds serum albumin, producing a 6–8 day half-life; a separate no-DAC form (also called Modified GRF 1-29) shares the same tetrasubstituted backbone but lacks the albumin-linking maleimidopropionyl-lysine and has a half-life of roughly 30 minutes. Not FDA-approved in any form; ConjuChem halted Phase 2 development around 2007 after a patient death in an HIV-lipodystrophy trial (ultimately judged by investigators to be unrelated to the drug, but development was terminated regardless).
Ipamorelin
CJC-1295
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
The seminal preclinical characterization (Raun et al., 1998) established ipamorelin as the first GHRP-receptor agonist with a GH-release selectivity comparable to GHRH, without raising ACTH or cortisol even at doses more than 200-fold above the ED50 for GH. Pharmacokinetic-pharmacodynamic modeling in healthy male volunteers (Gobburu et al., 1999) confirmed a roughly 2-hour half-life and dose-dependent GH response following IV infusion. The most advanced human study is Beck et al. (2014), a Phase 2, randomized, double-blind, placebo-controlled trial in 114 patients after bowel resection evaluating IV ipamorelin 0.03 mg/kg twice daily for postoperative ileus; the drug was well tolerated but did not separate from placebo on the primary endpoint (time to tolerance of solid food), and the sponsor discontinued development. There are no completed registrational trials in adult growth hormone deficiency, frailty, or body-composition indications. Use in wellness medicine for anti-aging, fat loss, or muscle gain is extrapolated from short-term GH/IGF-1 pharmacodynamic data and is not clinically validated.
Key references
In healthy adults, single SubQ doses of CJC-1295 (with DAC) elevated plasma GH 2- to 10-fold for ≥6 days and IGF-1 1.5- to 3-fold for 9–11 days (Teichman et al., JCEM 2006), and pulsatile GH secretion was preserved rather than suppressed during continuous stimulation (Ionescu & Frohman, JCEM 2006). Despite these Phase 1/2 findings, ConjuChem halted Phase 2 lipodystrophy development in 2006–2007 after a trial participant died of a myocardial infarction; the event was deemed most likely due to pre-existing coronary disease, but the program was not resumed. No CJC-1295 form is FDA-approved for any indication. Grey-market use almost always refers to the no-DAC / Modified GRF 1-29 form, often stacked with ipamorelin; neither variant is clinically validated for anti-aging, body composition, or performance indications.
Key references
Ipamorelin and CJC-1295 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Disclosed Labs